vs
Side-by-side financial comparison of FirstEnergy (FE) and Zoetis (ZTS). Click either name above to swap in a different company.
FirstEnergy is the larger business by last-quarter revenue ($3.8B vs $2.4B, roughly 1.6× Zoetis). Zoetis runs the higher net margin — 25.3% vs -1.3%, a 26.6% gap on every dollar of revenue. On growth, FirstEnergy posted the faster year-over-year revenue change (19.6% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $-30.0M). Over the past eight quarters, FirstEnergy's revenue compounded faster (7.5% CAGR vs 4.4%).
FirstEnergy Corp. is an electric utility headquartered in Akron, Ohio. It was established when Ohio Edison merged with Centerior Energy in 1997.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
FE vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.8B | $2.4B |
| Net Profit | $-49.0M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | -0.6% | 31.9% |
| Net Margin | -1.3% | 25.3% |
| Revenue YoY | 19.6% | 3.0% |
| Net Profit YoY | -118.8% | 3.8% |
| EPS (diluted) | $-0.08 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.8B | $2.4B | ||
| Q3 25 | $4.1B | $2.4B | ||
| Q2 25 | $3.4B | $2.5B | ||
| Q1 25 | $3.8B | $2.2B | ||
| Q4 24 | $3.2B | $2.3B | ||
| Q3 24 | $3.7B | $2.4B | ||
| Q2 24 | $3.3B | $2.4B | ||
| Q1 24 | $3.3B | $2.2B |
| Q4 25 | $-49.0M | $603.0M | ||
| Q3 25 | $441.0M | $721.0M | ||
| Q2 25 | $268.0M | $718.0M | ||
| Q1 25 | $360.0M | $631.0M | ||
| Q4 24 | $261.0M | $581.0M | ||
| Q3 24 | $419.0M | $682.0M | ||
| Q2 24 | $45.0M | $624.0M | ||
| Q1 24 | $253.0M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | -0.6% | 31.9% | ||
| Q3 25 | 20.0% | 37.0% | ||
| Q2 25 | 19.1% | 36.7% | ||
| Q1 25 | 20.0% | 36.5% | ||
| Q4 24 | 19.3% | 31.6% | ||
| Q3 24 | 19.5% | 36.6% | ||
| Q2 24 | 12.9% | 33.0% | ||
| Q1 24 | 18.6% | 34.1% |
| Q4 25 | -1.3% | 25.3% | ||
| Q3 25 | 10.6% | 30.0% | ||
| Q2 25 | 7.9% | 29.2% | ||
| Q1 25 | 9.6% | 28.4% | ||
| Q4 24 | 8.2% | 25.1% | ||
| Q3 24 | 11.2% | 28.6% | ||
| Q2 24 | 1.4% | 26.4% | ||
| Q1 24 | 7.7% | 27.4% |
| Q4 25 | $-0.08 | $1.37 | ||
| Q3 25 | $0.76 | $1.63 | ||
| Q2 25 | $0.46 | $1.61 | ||
| Q1 25 | $0.62 | $1.41 | ||
| Q4 24 | $0.45 | $1.29 | ||
| Q3 24 | $0.73 | $1.50 | ||
| Q2 24 | $0.08 | $1.37 | ||
| Q1 24 | $0.44 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $57.0M | — |
| Total DebtLower is stronger | $25.5B | — |
| Stockholders' EquityBook value | $12.5B | $3.3B |
| Total Assets | $55.9B | $15.5B |
| Debt / EquityLower = less leverage | 2.04× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $57.0M | — | ||
| Q3 25 | $1.4B | $2.1B | ||
| Q2 25 | $569.0M | $1.4B | ||
| Q1 25 | $132.0M | $1.7B | ||
| Q4 24 | $111.0M | $2.0B | ||
| Q3 24 | $439.0M | $1.7B | ||
| Q2 24 | $60.0M | $1.6B | ||
| Q1 24 | $888.0M | $2.0B |
| Q4 25 | $25.5B | — | ||
| Q3 25 | $25.5B | — | ||
| Q2 25 | $23.7B | — | ||
| Q1 25 | $21.2B | — | ||
| Q4 24 | $22.5B | — | ||
| Q3 24 | $21.6B | — | ||
| Q2 24 | $20.8B | — | ||
| Q1 24 | $21.7B | — |
| Q4 25 | $12.5B | $3.3B | ||
| Q3 25 | $12.8B | $5.4B | ||
| Q2 25 | $12.9B | $5.0B | ||
| Q1 25 | $12.6B | $4.7B | ||
| Q4 24 | $12.5B | $4.8B | ||
| Q3 24 | $12.4B | $5.2B | ||
| Q2 24 | $12.5B | $5.0B | ||
| Q1 24 | $12.4B | $5.1B |
| Q4 25 | $55.9B | $15.5B | ||
| Q3 25 | $55.9B | $15.2B | ||
| Q2 25 | $54.2B | $14.5B | ||
| Q1 25 | $52.8B | $14.1B | ||
| Q4 24 | $52.0B | $14.2B | ||
| Q3 24 | $50.8B | $14.4B | ||
| Q2 24 | $51.0B | $14.2B | ||
| Q1 24 | $51.3B | $14.3B |
| Q4 25 | 2.04× | — | ||
| Q3 25 | 1.99× | — | ||
| Q2 25 | 1.85× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 1.81× | — | ||
| Q3 24 | 1.74× | — | ||
| Q2 24 | 1.67× | — | ||
| Q1 24 | 1.75× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.1B | $893.0M |
| Free Cash FlowOCF − Capex | $-30.0M | $732.0M |
| FCF MarginFCF / Revenue | -0.8% | 30.7% |
| Capex IntensityCapex / Revenue | 30.7% | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $-1.0B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.1B | $893.0M | ||
| Q3 25 | $845.0M | $938.0M | ||
| Q2 25 | $1.1B | $486.0M | ||
| Q1 25 | $637.0M | $587.0M | ||
| Q4 24 | $1.0B | $905.0M | ||
| Q3 24 | $775.0M | $951.0M | ||
| Q2 24 | $1.1B | $502.0M | ||
| Q1 24 | $-40.0M | $595.0M |
| Q4 25 | $-30.0M | $732.0M | ||
| Q3 25 | $-471.0M | $805.0M | ||
| Q2 25 | $-136.0M | $308.0M | ||
| Q1 25 | $-368.0M | $438.0M | ||
| Q4 24 | $-250.0M | $689.0M | ||
| Q3 24 | $-229.0M | $784.0M | ||
| Q2 24 | $170.0M | $370.0M | ||
| Q1 24 | $-830.0M | $455.0M |
| Q4 25 | -0.8% | 30.7% | ||
| Q3 25 | -11.4% | 33.5% | ||
| Q2 25 | -4.0% | 12.5% | ||
| Q1 25 | -9.8% | 19.7% | ||
| Q4 24 | -7.9% | 29.7% | ||
| Q3 24 | -6.1% | 32.8% | ||
| Q2 24 | 5.2% | 15.7% | ||
| Q1 24 | -25.3% | 20.8% |
| Q4 25 | 30.7% | 6.7% | ||
| Q3 25 | 31.7% | 5.5% | ||
| Q2 25 | 36.0% | 7.2% | ||
| Q1 25 | 26.7% | 6.7% | ||
| Q4 24 | 40.7% | 9.3% | ||
| Q3 24 | 26.9% | 7.0% | ||
| Q2 24 | 28.7% | 5.6% | ||
| Q1 24 | 24.0% | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | 1.92× | 1.30× | ||
| Q2 25 | 4.04× | 0.68× | ||
| Q1 25 | 1.77× | 0.93× | ||
| Q4 24 | 4.00× | 1.56× | ||
| Q3 24 | 1.85× | 1.39× | ||
| Q2 24 | 24.71× | 0.80× | ||
| Q1 24 | -0.16× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FE
| Integrated Segment | $1.4B | 37% |
| Other | $1.4B | 36% |
| Stand Alone Transmission Segment | $466.0M | 12% |
| Industrial Customers | $167.0M | 4% |
| Mid Atlantic Interstate Transmission LLC | $118.0M | 3% |
| Transmission | $105.0M | 3% |
| Transmission Segment | $68.0M | 2% |
| Tr AIL | $63.0M | 2% |
| Internal Customers | $10.0M | 0% |
| Wholesale Sales | $6.0M | 0% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
